Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at …

May 2, 2024 · Alnylam Pharmaceuticals (ALNY) reported $494.33 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 54.8%. EPS of -$0.16 …

CouponFollow Extension

8%
OFF

Compared To Estimates, Alnylam (ALNY) Q1 Earnings: A Look At …

3 weeks from now

May 2, 2024 · Alnylam Pharmaceuticals (ALNY) reported $494.33 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 54.8%. EPS of -$0.16 …

yahoo.com

93%
OFF

Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue …

3 weeks from now

May 4, 2023 · Alnylam (ALNY) delivered earnings and revenue surprises of 28.93% and 3.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead …

yahoo.com

8%
OFF

Compared To Estimates, Alnylam (ALNY) Q1 Earnings: A Look At …

3 weeks from now

Alnylam Pharmaceuticals (ALNY) reported $494.33 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 54.8%. EPS of -$0.16 for the same period …

reportify.cc

184%
OFF

Alnylam (ALNY) Q3 Earnings: Taking A Look At Key Metrics

3 weeks from now

Nov 2, 2023 · For the quarter ended September 2023, Alnylam Pharmaceuticals (ALNY) reported revenue of $750.53 million, up 184% over the same period last year. EPS came in at $1.15, …

nasdaq.com

184%
OFF

Alnylam (ALNY) Q3 Earnings: Taking A Look At Key Metrics Versus …

3 weeks from now

Nov 2, 2023 · ALNY - Free Report) reported revenue of $750.53 million, up 184% over the same period last year. EPS came in at $1.15, compared to -$3.32 in the year-ago quarter.

zacks.com

2%
OFF

Alnylam (ALNY) Reports Q3 Earnings: What Key Metrics Have To Say

3 weeks from now

Oct 31, 2024 · The reported number represents a year-over-year change of +31.2%. Net Product Revenues- Amvuttra: $258.59 million compared to the $240.23 million average estimate …

yahoo.com

FAQs about Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at … Coupon?

How much will Alnylam Pharmaceuticals earn per share?

Zacks Research analyst A. Chakraborty now forecasts that the biopharmaceutical company will post earnings per share of $0.36 for the quarter, up from their previous estimate of $0.34. The consensus estimate for Alnylam Pharmaceuticals’ current full-year earnings is ($2.24) per share. ...

How much did Alnylam Pharmaceuticals lose in Q1 2022?

Alnylam Pharmaceuticals, Inc. ALNY incurred a loss of $2.00 per share in the first quarter of 2022, wider than the Zacks Consensus Estimate of a loss of $1.93. The loss includes stock-based compensation expenses and unrealized gain on equity securities. ...

Is Alnylam a good stock to buy now?

For Alnylam, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -13.38%. On the other hand, the stock currently carries a Zacks Rank of #3. ...

How did Alnylam perform in the just reported quarter?

Here is how Alnylam performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product revenues, net: $365.16 million versus the eight-analyst average estimate of $344 million. The reported number represents a year-over-year change of +32.2%. ...

How do I receive news & ratings for Alnylam Pharmaceuticals?

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter. ...

Who owns Alnylam Pharmaceuticals?

Jennison Associates LLC purchased a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $61,160,000. Strategic Financial Concepts LLC acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $41,529,000. ...